HER2+ Breast Cancer Breakthrough: Can a New Combo Overcome Treatment Resistance?
"A Phase I study reveals how adding dasatinib to trastuzumab and paclitaxel shows promise in fighting HER2-overexpressing breast cancer by targeting resistance mechanisms."
Personalized medicine is revolutionizing cancer treatment by targeting specific vulnerabilities in tumors. A prime example is the development of anti-HER2 therapies, which have significantly improved outcomes for patients with HER2-overexpressing breast cancers. Trastuzumab, a monoclonal antibody, has become a cornerstone of treatment, but resistance remains a major challenge.
While trastuzumab offers undeniable benefits, most patients with HER2-positive metastatic tumors eventually experience disease progression. This has spurred the development of novel agents like lapatinib, pertuzumab, and T-DM1. However, understanding and overcoming resistance mechanisms is crucial to further improve outcomes.
Researchers have identified several mechanisms that contribute to trastuzumab resistance, including the activation of alternative signaling pathways and intrinsic changes in the HER2 receptor itself. Among these, the activation of the cytosolic kinase SRC has emerged as a key player. A new study explores whether combining dasatinib, an SRC kinase inhibitor, with trastuzumab and paclitaxel can improve outcomes in patients with HER2-overexpressing breast cancer.
Why Resistance Matters
HER2-positive breast cancer has benefited substantially from targeted treatment, but treatment resistance remains an important concern. The scale and timing of resistance can vary among patients, making broad conclusions difficult without specific data. This uncertainty underscores the need for continued research into more durable treatment strategies.
Targeted Therapy and Resistance
Trastuzumab and other HER2-targeted therapies have improved outcomes for people with HER2-positive breast cancer, yet resistance can develop from the outset or emerge after treatment. Reviews describe potential contributors across genetic loci, molecular structure, signaling pathways, and the tumor microenvironment. Consequently, researchers are studying resistance mechanisms and new strategies designed to overcome treatment failure.
The Trastuzumab Milestone
Trastuzumab is a humanized monoclonal antibody that recognizes the HER2 protein encoded by the ERBB2 gene. Its introduction markedly improved the previously poor prognosis associated with HER2-amplified breast cancers and affected treatment in both early and advanced disease. However, primary and acquired resistance remained a major challenge, prompting investigation into mechanisms such as impaired antibody binding, PTEN loss, increased PI3K/Akt activity, and PDK1 changes.
Dasatinib: A New Weapon Against Trastuzumab Resistance?
Preclinical studies suggest that SRC inhibition can enhance trastuzumab activity. SRC was found to be activated in trastuzumab-resistant cells and breast cancer patients who progressed on the drug. By performing a tyrosine phosphoproteome analysis, researchers identified SRC as a mediator of resistance. In preclinical models, combining dasatinib with trastuzumab synergistically increased the antibody's activity, leading to DNA damage, cell cycle arrest, and apoptosis.
- Study Design: A "3+3" dose-escalation design was used, starting with two oral dose levels of dasatinib: 100mg (DL1) and 140 mg (DL2).
- Patient Population: Ten patients with HER2-overexpressing advanced breast cancer were enrolled.
- Recommended Dose: Dasatinib 100 mg daily was established as the recommended RP2D.
- Treatment Duration: The median number of administered cycles was 12 (range, 1 to 18).
A Moving Research Landscape
Recent research continues to examine why some HER2-positive tumors respond to treatment while others do not. Current discussions increasingly focus on treatment resistance and on whether combinations can produce more durable responses. Because this area remains under active investigation, proposed approaches should be distinguished from established clinical evidence.
Why Responses Can Fail
The introduction of trastuzumab substantially improved the prognosis associated with HER2-amplified breast cancer. Nevertheless, the cited review identifies both primary and acquired resistance to trastuzumab as a significant and common clinical problem. The initial success of therapy therefore does not eliminate the possibility of treatment failure.
Comparing HER2-Targeted Options
A population-based real-world study assessed the safety and effectiveness of biosimilar trastuzumab versus reference trastuzumab, Herceptin, for adjuvant treatment of patients with HER2-positive breast cancer in routine practice. Separately, trastuzumab deruxtecan, or T-DXd, is described as an antibody-drug conjugate used in HER2-low and HER2-positive metastatic breast cancer. The T-DXd literature also reports that resistance consistently develops, showing that newer drug formats do not remove the broader challenge of treatment resistance.
Hope for Overcoming Resistance
This Phase I study demonstrates the feasibility of combining dasatinib with trastuzumab and paclitaxel, showing a manageable toxicity profile. This is especially important because the addition of dasatinib did not appear to significantly increase toxicities compared to the standard regimen.
What the Evidence Suggests
Taken together, the available discussion points to treatment resistance as a central issue in HER2-positive breast cancer. A new combination may be promising, but its value depends on evidence showing improved and durable outcomes. Careful interpretation is especially important when research is still evolving.
The Next Research Questions
Future work is likely to focus on identifying which tumors are most likely to resist treatment and how therapies can be combined more effectively. Researchers may also need to distinguish mechanisms of primary resistance from those acquired during treatment. These directions remain areas for investigation rather than settled conclusions.
Beyond a Single Drug
Treatment resistance is not a single, uniform problem, and its causes may differ across tumors and treatment settings. This complexity can make it difficult to compare therapies or apply findings from one study broadly. Broader progress will require research that accounts for biological variation and real-world treatment conditions.
Patient-Centered Questions
For patients, the practical importance of a new combination lies in whether it can delay or overcome resistance without adding unacceptable burdens. Research findings must therefore be considered alongside treatment goals, side effects, access, and individual disease characteristics. Until stronger comparative evidence is available, expectations about breakthrough combinations should remain appropriately cautious.
The observed reduction in p-SRC expression confirms the drug's mechanism of action and supports the potential for this combination to overcome trastuzumab resistance. These findings align with preclinical models, suggesting that dasatinib enhances trastuzumab's activity by inhibiting the pAKT and pSRC pathways.
The ongoing Phase II study will further evaluate the efficacy of this combination in patients with HER2-positive breast cancer. If successful, this approach could provide a valuable new treatment option for patients who develop resistance to existing therapies, improving outcomes and quality of life.